Loading...
XKRX
226950
Market cap1.11bUSD
Dec 05, Last price  
119,600.00KRW
1D
-2.13%
1Q
34.84%
IPO
276.10%
Name

OliX Pharmaceuticals Inc

Chart & Performance

D1W1MN
XKRX:226950 chart
P/E
—
P/S
289.34
EPS
—
Div Yield, %
—
Shrs. gr., 5y
5.28%
Rev. gr., 5y
38.10%
Revenues
5.68b
-66.73%
907,617,931391,900,557243,966,300302,000,0001,130,327,0532,474,272,0923,674,356,7659,320,323,64517,064,275,4405,677,152,000
Net income
-40.66b
L+112.85%
-2,981,507,333-3,655,601,087-5,163,924,704-7,742,007,380-14,352,745,072-19,384,552,650-29,714,663,862-19,495,352,386-19,101,696,120-40,658,700,000
CFO
-28.04b
L+32.48%
-3,448,353,860-3,448,577,949-4,787,060,999-8,359,441,717-10,733,212,800-3,759,218,608-19,053,575,334-30,682,858,180-21,168,432,070-28,044,991,000
Dividend
Mar 15, 20220.285 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101 for skin scar; OLX102 for skin whitening; OLX103, an atopic dermatitis product; OLX104 for hair loss; OLX105, an anti-wrinkle product; and OLX106 for diabetic foot ulcer. Its products pipeline also comprise OLX301 for age-related macular degeneration retinal fibrosis; OLX304 for retinitis pigmentosa; OLX201 for lung fibrosis; OLX202 for asthma; OLX203 for influenza; OLX401 for neuropathic pain; OLX701 for liver fibrosis; and OLX701 for cancer immunotherapy. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA. OliX Pharmaceuticals, Inc. was founded in 2010 and is based in Suwon, South Korea.
URL
http://www.olixpharma.com/
IPO date
Jul 18, 2018
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT